Gunma Prefectural Cancer Center ( Site 3402)

Ōta, Gunma 373-8550

1 studies enrolling now · 1 studies all time

What they study most

Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) — Recruiting now